AOND-21 is under clinical development by Aptarion Biotech and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AOND-21’s likelihood of approval (LoA) and phase transition for Lung Adenocarcinoma took place on 14 Jan 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AOND-21 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AOND-21 overview

AOND-21 (formerly NOX-D21) is under development for the treatment of lung adenocarcinoma. The drug candidate acts by targeting complement component C5a. The drug candidate is based on the spiegelmers technology platform. Spiegelmers are mirror-image oligonucleotides either consisting of L-RNA or L-DNA building blocks or have the exact mirror-image behavior compared to natural nucleic acids. It was also under development for lung edema in bacterial pneumonia, septic shock, postoperative acute kidney injury and duchenne muscular dystrophy (DMD).

Aptarion Biotech overview

Aptarion Biotech is a biotechnology company focusing on the development of L-aptamers as therapeutics in areas of medical need. Aptarion Biotech is headquartered in Berlin, Germany.

Quick View AOND-21 LOA Data

Report Segments
  • Innovator
Drug Name
  • AOND-21
Administration Pathway
Therapeutic Areas
  • Cardiovascular
  • Genetic Disorders
  • Genito Urinary System And Sex Hormones
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.